Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials

Maurer Matthew J.; Ghesquieres Herve; Link Brian K.; Jais Jean-Philippe; Habermann Thomas M.; Thompson Carrie A.; Haioun Corinne; Allmer Cristine; Johnston Patrick B.; Delarue Richard; Micallef Ivana N.; Peyrade Frederic; Inwards David J.; Ketterer Nicolas; Farooq Umar; Fitoussi Olivier; Macon William R.; Molina Thierry J.; Syrbu Sergei; Feldman Andrew L.; Slager Susan L.; Weiner George J.; Ansell Stephen M.; Cerhan James R.; Salles Gilles A.; Witzig Thomas E.; Tilly Herve; Nowakowski Grzegorz S.

首页> 外文期刊>Journal of Clinical Oncology >Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials

【24h】

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials

机译：诊断到治疗间隔是新诊断的弥漫性大B细胞淋巴瘤的重要临床因素，对临床试验中的偏差有所意义

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2018年第16期|共13页
作者
Maurer Matthew J.; Ghesquieres Herve; Link Brian K.; Jais Jean-Philippe; Habermann Thomas M.; Thompson Carrie A.; Haioun Corinne; Allmer Cristine; Johnston Patrick B.; Delarue Richard; Micallef Ivana N.; Peyrade Frederic; Inwards David J.; Ketterer Nicolas; Farooq Umar; Fitoussi Olivier; Macon William R.; Molina Thierry J.; Syrbu Sergei; Feldman Andrew L.; Slager Susan L.; Weiner George J.; Ansell Stephen M.; Cerhan James R.; Salles Gilles A.; Witzig Thomas E.; Tilly Herve; Nowakowski Grzegorz S.;
展开▼
作者单位

Mayo Clin Rochester MN 55905 USA;

Univ Claude Bernard Lyon France;

Univ Iowa Iowa City IA USA;

Hop Necker Enfants Malad Paris France;

Mayo Clin Rochester MN 55905 USA;

Mayo Clin Rochester MN 55905 USA;

Grp Hosp Mondor Creteil France;

Mayo Clin Rochester MN 55905 USA;

Mayo Clin Rochester MN 55905 USA;

Hop Necker Enfants Malad Paris France;

Mayo Clin Rochester MN 55905 USA;

Ctr Antoine Lacassagne Nice France;

Mayo Clin Rochester MN 55905 USA;

Clin Bois Cerf Lausanne Switzerland;

Univ Iowa Iowa City IA USA;

Polyclin Bordeaux Nord Aquitaine Bordeaux France;

Mayo Clin Rochester MN 55905 USA;

Hop Necker Enfants Malad Paris France;

Univ Iowa Iowa City IA USA;

Mayo Clin Rochester MN 55905 USA;

Mayo Clin Rochester MN 55905 USA;

Univ Iowa Iowa City IA USA;

Mayo Clin Rochester MN 55905 USA;

Mayo Clin Rochester MN 55905 USA;

Univ Claude Bernard Lyon France;

Mayo Clin Rochester MN 55905 USA;

Ctr Lutte Canc Henri Becquerel Rouen France;

Mayo Clin Rochester MN 55905 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials [J] . Maurer Matthew J., Ghesquieres Herve, Link Brian K., Journal of Clinical Oncology . 2018,第16期

机译：诊断到治疗间隔是新诊断的弥漫性大B细胞淋巴瘤的重要临床因素，对临床试验中的偏差有所意义
2. QUALITY INITIATIVE IN CLINICAL PRACTICE: A SINGLE INSTITUTION APPRAISAL OF QUALITY METRICS IN THE MANAGEMENT OF NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA BASED ON THE AMERICAN SOCIETY OF HEMATOLOGY PRACTICE IMPROVEMENT MODULE [J] . Bischin A. M., Vishnu P., Aboulafia D., Journal of investigative medicine . 2019,第1期

机译：临床实践中的质量倡议：基于美国血液学实践改进模块的美国血液学综合大型B细胞淋巴瘤管理中的质量指标的单一机构评估
3. Quality Initiative in Clinical Practice: A Single-Institution Appraisal of Quality Metrics in the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma [J] . Alina M. Bischin, Prakash Vishnu, Ruqin Chen, Mayo Clinic Proceedings: Innovations, Quality & Outcomes . 2019,第4期

机译：临床实践中的质量倡议：新诊断弥漫性大B细胞淋巴瘤管理中质量指标的单一机构评估
4. PHASE I CLINICAL TRIAL OF MURINE CD20 DNA VACCINATION IN DOGS WITH B-CELL LYMPHOMA [C] . Philip J Bergman, Nicole F Leibman, Jedd D Wolchok, Annual conference of the Veterinary Cancer Society . 2008

机译：肝脏CD20 DNA疫苗接种的I阶段I临床试验用B细胞淋巴瘤
5. FGFR-2 (BEK) Expression in Diffuse Large B-Cell Lymphoma with Clinical Correlation. [D] . Benson, Jenna. 2013

机译：FGFR-2（BEK）在弥漫性大B细胞淋巴瘤中的表达与临床相关性。
6. Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials [O] . Matthew J. Maurer, Hervé Ghesquières, Brian K. Link, -1

机译：诊断到治疗的间隔是新诊断的弥漫性大B细胞淋巴瘤的重要临床因素在临床试验中有偏倚的含义
7. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. [O] . Chadburn, A, Chiu, A, Lee, JY, 2009

机译：艾滋病相关的弥漫性大B细胞淋巴瘤的免疫表型分析及其在AIDS恶性肿瘤联盟临床试验010和034中的临床意义。

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅